2021, Vol. 2, Issue 1, Part A
Circulating nucleic acids as biomarkers in breast cancer
Author(s): Alireza Heidari, Elena Locci and Silvia Raymond
Abstract: The "labeling" of nucleic acids (cell genetic information such as RNA or DNA) is not a new technology for monitoring them. However, current capabilities do not provide a complete picture of how tumor cells develop. What this platform, known as Clon Mapper, can do that was not possible before, is to go back in time and track how tumor cells change over time. This gives researchers the ability to see which cells "win" over fewer resistant cells, continue to clone themselves, and make the tumor more dangerous. By isolating these cells, researchers can better test which therapies work against them. Monitoring changes over time is the key to successful transmission therapies. Tumor cells adapt and become resistant to therapies, which is why patients can recover but experience a relapse later. This is one of the reasons why cancer treatment is so challenging; We do not have very good methods for early detection of cells sensitive to a drug and measuring their resistance. This resistance is the main cause of treatment failure in many cancer patients. CLL is a low-grade B cancer that is often monitored for months or even years before active treatment is needed. This treatment depends a lot on the patient's close supervision. In this study, Clon Mapper focuses on identifying cells that mimic themselves, the speed at which this process takes place, and its effect on the growth rate of surrounding cells over time. This allows for a more accurate analysis of the cell population and may lead to more customized treatment plans for patients.
Pages: 39-50 | Views: 673 | Downloads: 261
Download Full Article: Click Here
How to cite this article:
Alireza Heidari, Elena Locci, Silvia Raymond. Circulating nucleic acids as biomarkers in breast cancer. J Res Chem 2021;2(1):39-50.